DIA会员及用户请点击登录

登录

忘记用户 ID? or 忘记密码?

Not a Member?

创建账户并加入。

Ottawa Marriott Hotel

2017 年 10 月 17 日 7:00 上午 - 2017 年 10 月 18 日 3:00 下午

100 Kent Street , Ottawa, ON K1P5R7 , CANADA

DIA Annual Canadian Meeting

Session 3B: Biosimilars: Evolving Perspectives

Session Chair(s)

Loretta  Del Bosco

Loretta Del Bosco

Director, Regulatory Affairs Quality Assurance Operations

AbbVie Corporation, Canada

Gain an overview from two key North American Regulators from Health Canada and FDA, as well as from the Alliance for Safe Biologic Medicines on the exciting and evolving landscape of Biosimilars. Being at the forefront of the biosimilar discussion is key to the future of our health care system in Canada, and abroad. This session will highlight key concepts and challenges.

Speaker(s)

Leah  Christl, PhD

FDA Update: The Development and Approval of Biosimilar Products in the US

Leah Christl, PhD

Amgen, United States

Exec Director, Global Biosimilars Regulatory Affairs & Regulatory & R&D Policy

Harry  Gewanter

Understanding Canadian Prescriber Perspectives on Key Considerations for Biologics and Biosimilars

Harry Gewanter

Alliance for Safe Biologic Medicines, United States

Immediate Past Chair

Stephanie  Hardy, MPH, RAC

Biosimilars: An Update on Health Canada Activities

Stephanie Hardy, MPH, RAC

Health Canada, Canada

OPIC, Biologics and Genetic Therapies Directorate, HPFB

获得信息并保持参与

不要错失任何机会——请加入我们的邮件列表,了解DIA的观点和事件。